In vitro activity of gatifloxacin, a new fluoroquinolone, against 204 anaerobes compared to seven other compounds

Clinical Microbiology and Infection

Volumn 9, Issue 11, 2003, Pages 1133-1138

  Dubreuil, Luc ^a   Behra Miellet, J ^a   Neut, C ^a   Calvet, L ^a  

^a UNIV LILLE   (France)

Author keywords

Anaerobes; Antimicrobial susceptibility; Gatifloxacin

Indexed keywords

AGAR; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; CLINAFLOXACIN; CLINDAMYCIN; GATIFLOXACIN; GREPAFLOXACIN; IMIPENEM; LEVOFLOXACIN; LOMEFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ANAEROBIC BACTERIUM; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; BITE WOUND; COMPARATIVE STUDY; DILUTION; DRUG MECHANISM; EAR INFECTION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REFERENCE VALUE; RESPIRATORY TRACT INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION;

BACTERIA (MICROORGANISMS);

EID: 0242708739     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2003.00773.x     Document Type: Article

References (20)

1. Dubreuil L, Breuil J, Dublanchet A, Sedallian A. Survey of the susceptibility patterns of Bacteroides fragilis group strains in France from 1977 to 1992. Eur J Clin Microbiol Infect Dis 1992; 11: 1094-9.
2. Mory F, Loczniewski A, Bland S et al. Survey of anaerobic susceptibility patterns: a French multicentric study. Int J Antimicrob Agents 1998; 10: 229-36.
3. Fang H, Edlund C, Hedberg M, Nord CE. New findings in beta-lactam and metronidazole resistant Bacteroides fragilis group. Int J Antimicrob Agents 2002; 19: 361-70.
4. Ishida K, Kaku M, Irifune K et al. In-vitro and in-vivo activity of a new quinolone, AM-1155, against Mycoplasma pneumoniae. J Antimicrob Chemother 1994; 34: 875-83.
5. Miyasbita N, Niki Y, Kishimoto T, Nakajima M, Matsushima T. In vitro and in vivo activities of AM-1155, a new fluoroquinolone against Chlamydia spp. Antimicrob Agents Chemother 1997; 41: 1331-4.
6. Tomioka H, Saito H, Sato K. Comparative anti-mycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. Antimicrob Agents Chemother 1993; 37: 1259-63.
7. Wise R, Brenwald NP, Andrews JM, Boswell F. The activity of the methylpiperazinyl fluoroquinolone CG 550.1: a comparison with other fluoroquinolones. J Antimicrob Chemother 1997; 39: 447-52.
8. Summanen P, Baron EJ, Citron DM, Strong CA, Wexler HM, Finegold SM. Advanced identification method. In: Summanen P, Baron E, Strong C, Wexler H, Finegold SM, eds. Wadsworth anaerobic bacteriology manual, 5th edn. Belmont, CA: Star Publishing Co., 1993.
9. National Committee for Clinical Laboratory Standards. Methods for antimicrobial testing of anaerobic bacteria, 2nd edn; Approved standard, 4th edn. M11-A4. Villanova, Pa: NCCLS, 1997.
10. Acar J, Carret G, Cavallo JD et al. Communiqué de l'antibiogramme de la Société Française de microbiologie. Valeurs critiques pour l'antibiogramme. Path Biol 1998; 46: 1-16.
11. Mikamo H, Kawazoe K, Sato Y, Hayasaki Y, Tamaya T. In vitro and in vivo antibacterial activities of AM-1155 in the fields of obstetrics and gynecology. Chemotherapy 1998; 44: 238-42.
12. Kato N, Kato H, Tanaka-Bandoh K, Watanabe K, Vena K. Comparative in-vitro and in-vivo activity of AM-1.155 against anaerobic bacteria. J Antimicrob Chemother 1997; 40: 631-7.
13. Erwin ME, Jones M, Barrett MS, Pfaller MA, Hayward CL, Doern GV. Comparative antimicrobial activity of gatifloxacin, a new 8-methoxyfluoroquinolone, tested against Campylobacter jejuni and anaerobic bacteria [abstract E-191]. In: Program and Abstracts of 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998: 224.
14. Schaumann R, Ackermann G, Pless B, Claros MC, Rodloff AC. In vitro activity of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria. Antimicrob Agents Chemother 1999; 43:2783-6.
15. Ednie LM, Jacobs R, Appelbaum PC. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob Agents Chemother 1998; 42: 2459-62.
16. Alexander CJ, Goldstein EJC, Citron DM, Decherney AH. Review of the comparative in vitro susceptibilities of lower female genital tract pathogens to older and newer fluoroquinolones. Anaerobe 2000; 6: 313-23.
17. Goldstein EJC, Citron DM, Merriam CV, Tyrrell K, Warren Y. Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections. Antimicrob Agents Chemother 1999; 43: 1475-9.
18. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997; 40: 639-51.
19. Milatovic D, Schmitz FJ, Brisse S, Verhoef J, Fluit ADC. In vitro activities of sitafloxacin (DU 6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob Agents Chemother 2000; 44: 1102-7.
20. Fung-Tomc J, Minassian B, Kolek B, Washo T, Huczko E, Bonner D. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother 2000; 45: 437-46.